The Lewy Body Diseases Biomarker Workshop included: 1) keynote sessions on the current state of biomarker research for LBD and PD; 2) comparison of platforms used to examine peripheral biomarkers for disease progression and drug responsiveness; 3) analysis of the feasibility of clinical non-motor biomarkers for measurement of disease progression and biomarker signature development; 4) lessons learned from complementary efforts; 5) analysis of the feasibility of neuroimaging outcomes to develop a biomarker disease signature; and 6) consensus building for common data elements (CDEs), data formats, and biospecimen collection and distribution. Working groups for biospecimens/biofluids, clinical, genetics, pathology and imaging were established prior to the workshop. Each working group focused on defining the current state of biomarker research in the designated area and identification of the next steps required to move biomarker discovery and validation towards clinical utility.
Margaret Sutherland, Ph.D.
National Institute of Neurological Disorders and Stroke
Phone: (301) 496-5680
Last Modified October 18, 2015